|
Mar 13
|
HeartSciences Provides Business Update and Reports Third Quarter Fiscal 2025 Financial Results
|
|
Mar 10
|
HeartSciences Inc. Engages Integrous Communications to Enhance Investor Communications
|
|
Jul 29
|
HeartSciences Provides Business Update and Reports Fiscal 2024 Financial Results
|
|
Jul 26
|
Innovation Value Institute Analysis Demonstrates HeartSciences’ MyoVista® wavECG™ Potential to Improve Cardiovascular Pathway Efficiency
|
|
Jul 25
|
HeartSciences Selected to Demonstrate MyoVista® wavECG™ at the United Nations General Assembly Digital Health Symposium as a Technology to Radically Transform Healthcare
|
|
May 20
|
HeartSciences Announces Further Internationalization of its AI-ECG Patent Portfolio
|
|
Feb 1
|
HeartSciences Appoints New Scientific Advisory Board Member
|
|
Jan 3
|
HeartSciences Reminds Stockholders to Vote at the Upcoming Annual Shareholder Meeting
|
|
Dec 14
|
HeartSciences Reports Second Quarter Fiscal 2024 Financial Results
|
|
Dec 5
|
HeartSciences Receives FDA Confirmation for 510(k) Clearance Pathway
|
|
Aug 24
|
HeartSciences’ MyoVista® wavECGTM Selected to be used in Irish Heart Screening Evaluation
|
|
May 2
|
HeartSciences to Participate in The Benchmark Company’s Virtual Individual Investor Healthcare Conference
|